Recap: Telesis Bio Q3 Earnings
Portfolio Pulse from Benzinga Insights
Telesis Bio (NASDAQ:TBIO) reported Q3 earnings with an EPS of $-0.37, missing estimates by 23.33% compared to the expected $-0.3. Revenue decreased by $1.11 million from the same period last year. The company's stock price dropped by 5.76% the day after beating EPS estimates last quarter.
November 13, 2023 | 9:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Telesis Bio reported lower than expected Q3 earnings and a decrease in revenue compared to last year, which may negatively impact the stock price in the short term.
Given the earnings miss and the historical reaction of a 5.76% drop in share price after a previous earnings beat, it is likely that the stock price will be negatively affected in the short term. The relevance is high as the news is directly about TBIO's financial performance, and the importance is significant due to the impact earnings reports typically have on stock prices. The confidence level is not at 100 due to market unpredictability and other external factors that could influence stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100